iRhythm Technologies, Inc. (IRTC) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $123.56 (-3.32%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 15, 2026 | Richard Newitter | Truist Financial | $170.00 | +37.6% |
| Feb 20, 2026 | Richard Newitter | Truist Financial | $200.00 | +61.9% |
| Jan 5, 2026 | Vijay Kumar | Evercore ISI | $210.00 | +70.0% |
| Oct 31, 2025 | David Roman | Goldman Sachs | $202.00 | +63.5% |
| Oct 31, 2025 | David Rescott | Robert W. Baird | $235.00 | +90.2% |
| Oct 31, 2025 | Gene Mannheimer | Loop Capital Markets | $220.00 | +78.1% |
| Oct 31, 2025 | David Saxon | Needham | $244.00 | +97.5% |
| Oct 15, 2025 | Richard Newitter | Truist Financial | $205.00 | +65.9% |
| Oct 10, 2025 | David Rescott | Robert W. Baird | $220.00 | +78.1% |
| Aug 28, 2025 | David Saxon | Needham | $193.00 | +56.2% |
| Jul 14, 2025 | Marie Thibault | BTIG | $165.00 | +33.5% |
| May 5, 2025 | Richard Newitter | Truist Financial | $146.00 | +18.2% |
| Jan 8, 2025 | Suraj Kalia | Oppenheimer | $120.00 | -2.9% |
| Oct 31, 2024 | Michael Matson | Needham | $96.00 | -22.3% |
| Oct 22, 2024 | David Rescott | Truist Financial | $95.00 | -23.1% |
| Oct 15, 2024 | David Rescott | Robert W. Baird | $100.00 | -19.1% |
| Oct 14, 2024 | Richard Newitter | Truist Financial | $80.00 | -35.3% |
| Oct 4, 2024 | David Roman | Goldman Sachs | $78.00 | -36.9% |
| Sep 25, 2024 | William Plovanic | Canaccord Genuity | $137.00 | +10.9% |
| Aug 2, 2024 | Richard Newitter | Truist Financial | $117.00 | -5.3% |
Top Analysts Covering IRTC
IRTC vs Sector & Market
| Metric | IRTC | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 15 | 8 | 19 |
| Target Upside | +40.2% | +153002.0% | +21.5% |
| P/E Ratio | -90.83 | 3.56 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $876M | $876M | $876M | 11 |
| 2027-03-31 | $224M | $228M | $230M | 4 |
| 2027-06-30 | $249M | $253M | $256M | 6 |
| 2027-09-30 | $253M | $257M | $259M | 4 |
| 2027-12-31 | $277M | $282M | $285M | 7 |
| 2028-03-31 | $259M | $263M | $266M | 3 |
| 2028-06-30 | $286M | $291M | $294M | 5 |
| 2028-09-30 | $288M | $292M | $296M | 3 |
| 2028-12-31 | $314M | $319M | $323M | 6 |
| 2029-12-31 | $1.36B | $1.37B | $1.40B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.09 | $-0.30 | $0.57 | 7 |
| 2027-03-31 | $-0.44 | $-0.44 | $-0.43 | 2 |
| 2027-06-30 | $0.12 | $0.12 | $0.12 | 2 |
| 2027-09-30 | $0.25 | $0.26 | $0.26 | 2 |
| 2027-12-31 | $0.70 | $0.71 | $0.72 | 2 |
| 2028-03-31 | $-0.08 | $-0.08 | $-0.07 | 3 |
| 2028-06-30 | $0.41 | $0.42 | $0.43 | 3 |
| 2028-09-30 | $0.62 | $0.64 | $0.64 | 3 |
| 2028-12-31 | $0.98 | $1.00 | $1.01 | 3 |
| 2029-12-31 | $2.37 | $2.40 | $2.45 | 1 |
Frequently Asked Questions
What is the analyst consensus for IRTC?
The consensus among 15 analysts covering iRhythm Technologies, Inc. (IRTC) is Buy with an average price target of $174.88.
What is the highest price target for IRTC?
The highest price target for IRTC is $244.00, set by David Saxon at Needham on 2025-10-31.
What is the lowest price target for IRTC?
The lowest price target for IRTC is $78.00, set by David Roman at Goldman Sachs on 2024-10-04.
How many analysts cover IRTC?
15 analysts have issued ratings for iRhythm Technologies, Inc. in the past 12 months.
Is IRTC a buy or sell right now?
Based on 15 analyst ratings, IRTC has a consensus rating of Buy (2.00/5) with a +40.2% upside to the consensus target of $174.88.
What are the earnings estimates for IRTC?
Analysts estimate IRTC will report EPS of $-0.30 for the period ending 2026-12-31, with revenue estimated at $876M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.